Anthracycline-Induced Cardiomyopathy

Abstract

Anthracyclines are potent chemotherapeutic agents associated with 3 different forms of cardiomyopathy. Acute cardiomyopathy is seen within 3 months of drug exposure and may take the form of either a reversible myocarditis and pericarditis or an early-onset type and a late-onset type of chronic cardiomyopathy. Chronic anthracycline-induced cardiomyopathy is treated similarly to ischemic cardiomyopathies with beta-blockade and angiotensin-converting enzyme (ACE) inhibition. This review focuses on recent research regarding mechanisms of anthracycline-induced myocardial damage, the noninvasive imaging diagnosis of anthracycline-induced cardiomyopathy, and potential areas of future research regarding genetic screening and selecting individuals at increased risk, with consideration of prophylactic treatment with medications, specifically Carvedilol and ACE inhibitors.

Keywords:

• anthracycline
• cardiomyopathy
• cardiotoxicity
• daunorubicin
• doxorubicin
• Adriamycin®